13F-HR filed by Spruce Street Capital LP
Spruce Street Capital LP filed this 13F-HR for the quarter ended 2026-06-30, filed 2026-08-13, with 30 holding rows worth $509,681,144.
- Accession
- 0002050194-26-000005
- Filer
- CIK 2050194
- Filed
- 2026-08-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2026
A holdings report, 30 entries on the cover page, a total value of $509,681,144 stated on the cover page (in dollars after the unit check, H1), rows summing to $509,681,144 with VALUE read as dollars as filed, 13F file number 028-26325. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A | G52694109 | Stock | 918,070 | $58,710,577 | dollars as filed | |
| RELAY THERAPEUTICS INC COM | 75943R102 | Stock | 2,984,125 | $55,832,979 | dollars as filed | |
| LB PHARMACEUTICALS INC | 50180M108 | COMMON STOCK | 1,376,159 | $44,663,240 | dollars as filed | |
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 6,391,328 | $44,227,990 | dollars as filed | |
| ALTO NEUROSCIENCE INC COM SHS | 02157Q109 | Stock | 1,353,047 | $35,706,910 | dollars as filed | |
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 354,816 | $34,587,464 | dollars as filed | |
| ALKERMES PLC | G01767105 | SHS | 543,876 | $28,496,383 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 3,452,576 | $21,267,868 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 306,047 | $17,790,512 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 329,006 | $16,697,055 | dollars as filed | |
| ENANTA PHARMACEUTICALS INC | 29251M106 | COM | 1,088,731 | $15,873,698 | dollars as filed | |
| PERSPECTIVE THERAPEUTICS INC | 46489V302 | COMMON STOCK | 3,693,931 | $12,596,305 | dollars as filed | |
| Inflarx Nv | N44821101 | COM | 5,352,198 | $11,988,924 | dollars as filed | |
| SURROZEN INC | 86889P208 | COMMON STOCK | 432,040 | $11,211,438 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 392,574 | $11,047,032 | dollars as filed | |
| CENTURY THERAPEUTICS INC | 15673T100 | COM | 4,059,054 | $9,944,682 | dollars as filed | |
| MINERVA NEUROSCIENCES INC | 603380205 | COM NEW | 1,655,500 | $9,188,025 | dollars as filed | |
| SAB BIOTHERAPEUTICS INC | 78397T202 | COMMON STOCK | 2,198,502 | $8,574,158 | dollars as filed | |
| AN2 THERAPEUTICS INC | 037326105 | COM | 1,661,073 | $8,039,593 | dollars as filed | |
| ERASCA INC COM | 29479A108 | Stock | 422,543 | $7,740,988 | dollars as filed | |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 3,581,603 | $7,270,654 | dollars as filed | |
| Research Alliance Corp Iii Ord Shs Cl A | G75226103 | Common Stock | 500,000 | $5,350,000 | dollars as filed | |
| HELIX ACQUISITION CORP III | G4444S107 | USD CL A ORD SHS | 500,000 | $5,320,000 | dollars as filed | |
| ZAI LAB LTD ADR | 98887Q104 | ADR | 279,110 | $5,303,090 | dollars as filed | |
| ACHIEVE LIFE SCIENCES INC | 004468500 | COMMON STOCK | 736,637 | $4,810,240 | dollars as filed | |
| LEXEO THERAPEUTICS INC | 52886X107 | COMMON STOCK | 928,593 | $4,322,600 | dollars as filed | |
| ALECTOR INC | 014442107 | COMMON STOCK | 2,101,068 | $4,223,147 | dollars as filed | |
| LeonaBio Inc | 04746L203 | COM | 393,701 | $3,618,112 | dollars as filed | |
| CORVUS PHARMACEUTICALS INC | 221015100 | COM | 231,585 | $3,459,880 | dollars as filed | |
| JATT II ACQUISITION CORP | G50765109 | ORD SHS | 160,000 | $1,817,600 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0002050194-26-000005 | this filing | 2026-08-13 | acceptance time not in the bulk data set |